Edwards Lifesciences Corporation v. Meril Life Sciences Pvt. Ltd.

I. BACKGROUND

Plaintiffs Edwards Lifesciences Corporation and Edwards Lifesciences LLC (collectively, “Edwards”) develop and supply devices for the treatment of heart disease, including artificial heart valves. Dkt. No. 1 (“Complaint”) ¶ 5. Defendant Meril Life Sciences PVT. Ltd. (“Meril”) is an Indian company that markets “Myval”-branded transcatheter aortic valves in India and Europe. Id. ¶ 27. Meril distributes Myval valves as part of the “Myval System.” Id. ¶ 32. According to the Complaint, Meril does not have FDA approval to market the Myval System in the United States and has not yet sought such approval. Id. ¶ 33. Meril, Inc. (“Meril USA”) is Meril’s United States subsidiary. Id. ¶ 27. In September 2019, officers of both Meril and Meril USA attended the 2019 Transcatheter Cardiovascular Therapeutics Conference (“TCT Conference”) in San Francisco, California. Id. ¶ 34. Meril exhibited its Myval System at the TCT conference and then publicized its exhibition on its LinkedIn page. Id. ¶ 35 (stating that Meril’s booth at the conference “exhibited the MeRes100 and Myval TAVR system”). Edwards…